Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Ritlecitinib Trial in Moderately to Severely Active Ulcerative Colitis
2021-003702-42Phase 3Terminated
- Sponsor
- Pfizer
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis comparing Ritlecitinib with Placebo (2 arms). Started May 2022; status: terminated.
02
Drugs
ritlecitinib tosilate
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2021-003702-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003702-42.